Last reviewed · How we verify

NCT05755425

CPAP Versus HFNO for the Treatment of Acute Hypoxemic Respiratory Failure Due to Community Acquired Pneumonia

Status unknown Last updated 6 March 2023
What this trial tests

trial testing CPAP in Pneumonia in 100 participants. Status unknown.

Timeline
22 February 2022
Primary endpoint
20 December 2023
30 January 2024

Quick facts

Lead sponsorEvangelismos Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date22 February 2022
Primary completion20 December 2023
Estimated completion30 January 2024
Sites2 locations across Greece

Drugs / interventions tested

Conditions studied

Sponsor

Evangelismos Hospital

Who can join

Adults 18 to 90, any sex, with Pneumonia or Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the study compares two non-invasive respiratory support modalities ie CPAP and High Flow nasal cannula oxygen for the treatment of severe hypoxemic respiratory failure attributed to Community acquired Pneumonia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CPAP

Trials testing the same drug.

Other recruiting trials for Pneumonia

Currently open trials in the same condition.

Other Evangelismos Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05755425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing